| __timestamp | Vertex Pharmaceuticals Incorporated | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 60987000 | 4050200000 |
| Thursday, January 1, 2015 | 125542000 | 5047100000 |
| Friday, January 1, 2016 | 210460000 | 6078400000 |
| Sunday, January 1, 2017 | 275119000 | 6931500000 |
| Monday, January 1, 2018 | 409539000 | 6861900000 |
| Tuesday, January 1, 2019 | 547758000 | 7056300000 |
| Wednesday, January 1, 2020 | 736300000 | 8149300000 |
| Friday, January 1, 2021 | 904200000 | 12310800000 |
| Saturday, January 1, 2022 | 1080300000 | 9765700000 |
| Sunday, January 1, 2023 | 1262200000 | 8988300000 |
| Monday, January 1, 2024 | 1530500000 |
Cracking the code
In the competitive landscape of pharmaceuticals, cost efficiency is paramount. Vertex Pharmaceuticals Incorporated and Viatris Inc. have been pivotal players, each with distinct strategies. From 2014 to 2023, Vertex's cost of revenue surged by over 1,900%, reflecting its aggressive expansion and investment in innovative treatments. In contrast, Viatris, formed in 2020, maintained a relatively stable cost structure, peaking in 2021 with a 30% increase from 2020, before a gradual decline.
Vertex's cost efficiency improved significantly, with costs rising from $61 million in 2014 to $1.26 billion in 2023. Meanwhile, Viatris, despite its higher baseline, showcased a strategic cost reduction from $12.31 billion in 2021 to $8.99 billion in 2023. This comparison highlights the diverse approaches in managing operational costs, offering insights into their financial health and strategic priorities.
Cost of Revenue: Key Insights for AstraZeneca PLC and Viatris Inc.
Cost of Revenue Comparison: Vertex Pharmaceuticals Incorporated vs Takeda Pharmaceutical Company Limited
Cost of Revenue: Key Insights for Vertex Pharmaceuticals Incorporated and United Therapeutics Corporation
Cost of Revenue Trends: Vertex Pharmaceuticals Incorporated vs Incyte Corporation
Cost of Revenue Trends: Vertex Pharmaceuticals Incorporated vs Halozyme Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs Jazz Pharmaceuticals plc
Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs Grifols, S.A.
Cost of Revenue: Key Insights for Viatris Inc. and Jazz Pharmaceuticals plc
Viatris Inc. vs Ionis Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Viatris Inc. vs Vericel Corporation
Cost of Revenue: Key Insights for Viatris Inc. and Taro Pharmaceutical Industries Ltd.
Viatris Inc. vs MiMedx Group, Inc.: Efficiency in Cost of Revenue Explored